Changes in the expression and methylation levels of the MMP-2, MMP-9, TIMP-1, TIMP-2 and VEGF-A genes in children with acute lymphoblastic leukemia

被引:0
|
作者
Inandiklioglu, Nihal [1 ]
Demirhan, Osman [1 ]
Bayram, Ibrahim [2 ]
Tanyeli, Atilla [2 ]
机构
[1] Cukurova Univ, Fac Med, Dept Med Biol, Adana, Turkey
[2] Dept Pediat Oncol, Adana, Turkey
来源
CUKUROVA MEDICAL JOURNAL | 2021年 / 46卷 / 02期
关键词
Acute lymphoblastic leukemia; MMP; TIMP; VEGF-A; ENDOTHELIAL GROWTH-FACTOR; BONE-MARROW; MATRIX METALLOPROTEINASES; ANGIOGENESIS;
D O I
10.17826/cumj.856752
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The aim of this article is to show the expression and methylation levels of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and vascular endothelial growth factor (VEGF)genes in patients diagnosed with childhood acute lymphoblastic leukemia (ALL) and their relationship with clinical findings. Materials and Methods: In this study, we determined the expression level and methylation percentage of MMP2, MMP9, TIMP1, TIMP2 and VEGF-A genes between patients with childhood ALL and healthy children. Expression and methylation analyzes were performed by RT-PCR. The results of MMP2, MMP9, TIMP1, TIMP2, VEGF-A and other clinical parameters were compared between the two groups. Results: The expression levels of MMP2 (2.55-fold), MMP9 (5.06-fold), TIMP1 (2.91-fold) and VEGF-A (4.76-fold) was significantly higher in the patients, but the same results were not found for TIMP-2. The methylation levels of MMP2 (29.74%), MMP9 (30.98%), TIMP2 (11.91%) and VEGF-A (6.55%) were significantly higher in the patients than in the controls. Conclusion: MMP2, MMP9 and VEGF-A genes have high expression and methylation levels. These results make this complex structure intriguing in childhood ALL for further studies and reinforce the emphasis that it should be investigated.
引用
收藏
页码:825 / 833
页数:9
相关论文
共 50 条
  • [31] SERUM MATRIX METALLOPROTEINASES MMP-2 AND MMP-9 AND METALLOPROTEINASE TISSUE INHIBITORS TIMP-1 AND TIMP-2 IN PATIENTS WITH ACUTE KIDNEY
    Zakiyanov, Oskar
    Kalousova, Marta
    Kriha, Vitezslav
    Vachek, Jan
    Zima, Tomas
    Tesar, Vladimir
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 409 - 409
  • [32] MRNA EXPRESSION OF MMP-2 AND MMP-9 AND TIMP-1 AND TIMP-2 IN CHILDHOOD ALL: POTENTIAL ROLE OF TIMP1 AS AN ADVERSE PROGNOSTIC FACTOR
    Scrideli, Carlos
    Cortez, Maria Angelica
    Yunes, Jose Andres
    Queiroz, Rosane de Paula
    Valera, Elvis Terci
    Toledo, Silvia
    Pavoni-Ferreira, Patricia
    Lee, Maria Lucia
    Petrilli, Antonio Sergio
    Brandalise, Silvia Regina
    Tone, Luiz Gonzaga
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 762 - 762
  • [33] Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary
    Sakata, K
    Shigemasa, K
    Nagai, N
    Ohama, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2000, 17 (04) : 673 - 681
  • [34] Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease
    Lorenzl, S
    Albers, DS
    Narr, S
    Chirichigno, J
    Beal, MF
    EXPERIMENTAL NEUROLOGY, 2002, 178 (01) : 13 - 20
  • [35] MMP-2, MMP-9 and their inhibitors, TIMP-1, TIMP-2 and TIMP-3 expression at the endometrial myometrial interface (EMI) of human uterine adenomyosis
    Huang, H.
    Huang, T.
    Yue, H.
    Wang, H.
    Lai, C.
    Soong, Y.
    HUMAN REPRODUCTION, 2007, 22 : I187 - I188
  • [36] THE CLINICAL SIGNIFICANCE OF TIMP-1, TIMP-2, MMP-2, MMP-9, OSTEOPROTEGERIN, SRANKL, AND ISS IN MULTIPLE MYELOMA PATIENTS
    Oliveira, L. C.
    Uzielli, J. A.
    Baggio, M. S.
    Lange, A. P.
    Tanus-Santos, J. E.
    Rego, E. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 389 - 389
  • [37] The gelatinases MMP-2, MMP-9 and their inhibitors TIMP-1, TIMP-2 are constitutively expressed by uterine natural killer cells
    Bianco, J. E. R.
    Rosa, R. G.
    Lippe, E. M.
    Joazeiro, P. P.
    Yamada, A. T.
    PLACENTA, 2008, 29 (01) : 112 - 112
  • [38] Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy
    Kapelko-Slowik, Katarzyna
    Slowik, Miroslaw
    Szalinski, Marek
    Dybko, Jaroslaw
    Wolowiec, Dariusz
    Prajs, Iwona
    Bohdanowicz-Pawlak, Anna
    Biernat, Monika
    Urbaniak-Kujda, Donata
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 27 (01): : 99 - 103
  • [39] Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases
    Jakubowska, Katarzyna
    Pryczynicz, Anna
    Iwanowicz, Piotr
    Niewinski, Andrzej
    Maciorkowska, Elzbieta
    Hapanowicz, Jerzy
    Jagodzinska, Dorota
    Kemona, Andrzej
    Guzinska-Ustymowicz, Katarzyna
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2016, 2016
  • [40] Regulation of mRNAs encoding MMP-9 and MMP-2, and their inhibitors TIMP-1 and TIMP-2 by androgens in the rat ventral prostate
    Limaye, Anil M.
    Desai, Kartiki V.
    Chavalmane, Aravinda K.
    Kondaiah, Paturu
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 294 (1-2) : 10 - 18